Abstract:The sonic hedgehog (SHH) signaling pathway exhibits aberrant activation in triple-negative breast cancer (TNBC), wherein it regulates several malignant phenotypes related to tumor metastasis. GANT61, an inhibitor of the SHH signaling pathway, may offer promise when administered in combination with conventional chemotherapy to treat metastatic TNBC. However, poor bioavailability and substantial off-target toxicity limit its clinical application. To address these limitations, we designed a peptide-functionalized dual-targeting delivery system encapsulating paclitaxel and GANT61 in tLyP-1 peptide-modified reconstituted high-density lipoprotein nanoparticle (tLyP-1-rHDL-PTX/GANT61 NP) for metastatic TNBC treatment. The apolipoprotein A-1 and tLyP-1 peptide modified on the surface of nanoparticles enable the delivery system to target tumor cells by binding to the overexpressed scavenger receptor B type I and neuropilin-1 receptor. Moreover, the tLyP-1 peptide also enables the deep tumor penetration of nanoparticles further facilitating paclitaxel and GANT61 delivery. Increased cellular uptake of the nanoparticles was observed in both MDA-MB-231, BT-549 tumor cells, and their 3D tumor spheroids. A series of <i>in vitro</i> experiments reveal that GANT61 was able to suppress key metastasis-related tumor cell activities including angiogenesis, migration, invasion, and stemness. Owing to more effective drug administration, the metastasis suppression efficiency of GANT61 was significantly enhanced by the dual-targeting tLyP-1-rHDL delivery system. Meanwhile, the codelivery of paclitaxel and GANT61 by dual-targeting tLyP-1-rHDL nanoparticles demonstrated superior efficiency of disrupting proliferation and inducing apoptosis in tumor cells compared with drug solutions. In a spontaneous metastasis breast cancer NCG mice model, the tLyP-1-rHDL-PTX/GANT61 nanoparticles exhibited highly tumor-specific distribution and result in significant inhibition of the primary tumor growth and dramatic reduction of lung metastasis without obvious side effects. The present work suggests that a combination of the SHH signaling pathway suppression and chemotherapy assisted by peptide-functionalized targeting tLyP-1-rHDL nanoparticles may provide a promising strategy for metastatic TNBC treatment.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.1c02074?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.1c02074</a>.Expression levels of NRP-1 and SR-B1 in TNBC cells; tumor penetration efficiency of NPs in BT-549 spheroids; prognostic significance of GLI1 gene expression in breast cancer; efficiencies of NPs to inhibited GLI1; efficiencies of NPs to inhibited Vimentin, Snail, and E-cadherin; H&E staining of major organs; and hematology analysis (<a class="ext-link" href="/doi/suppl/10.1021/acsami.1c02074/suppl_file/am1c02074_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Reducing Interstitial Fluid Pressure and Inhibiting Pulmonary Metastasis of Breast Cancer by Gelatin Modified Cationic Lipid Nanoparticles.

Radiosensitizer-based Injectable Hydrogel for Enhanced Radio-Chemotherapy of TNBC

Intelligently Targeted Drug Delivery and Enhanced Antitumor Effect by Gelatinase-Responsive Nanoparticles

Injectable nano-in situ-thermosensitive-hydrogels based on halofuginone and silver for postoperative treatment against triple-negative breast cancer

Synergistic Inhibition of Migration and Invasion of Breast Cancer Cells by Dual Docetaxel/quercetin-Loaded Nanoparticles Via Akt/MMP-9 Pathway.

Enhanced antitumor efficacy by d-glucosamine-functionalized and paclitaxel-loaded poly(ethylene glycol)-co-poly(trimethylene carbonate) polymer nanoparticles.

iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability

Efficient Antitumor Effect of Co-Drug-loaded Nanoparticles with Gelatin Hydrogel by Local Implantation

Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis

Integrin-mediated active tumor targeting and tumor microenvironment response dendrimer-gelatin nanoparticles for drug delivery and tumor treatment.

Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression

Anticancer Drug-Loaded Multifunctional Nanoparticles to Enhance the Chemotherapeutic Efficacy in Lung Cancer Metastasis.

Inhibition of Growth and Lung Metastasis of Breast Cancer by Tumor-Homing Triple-Bioresponsive Nanotherapeutics

Nanostructured lipid carriers loaded into in situ gels for breast cancer local treatment

474P Evaluation of Gelatinase-Responsive Copolymeric Nanoparticles Targeting PD-1 and TGF-β Pathways for Treating Immune-Resistant Tumor

Enhanced Anticancer Efficacy of Dual Drug-Loaded Self-Assembled Nanostructured Lipid Carriers Mediated by pH-Responsive Folic Acid and Human-Derived Cell Penetrating Peptide dNP2

Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer

Micellar Nanoparticles Inhibit Breast Cancer and Pulmonary Metastasis by Modulating the Recruitment and Depletion of Myeloid-Derived Suppressor Cells.

Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment

Size-transformable Gelatin/nanochitosan/doxorubicin Nanoparticles with Sequentially Triggered Drug Release for Anticancer Therapy.

Highly Stable Fluorinated Nanocarriers with Irgd for Overcoming the Stability Dilemma and Enhancing Tumor Penetration in an Orthotopic Breast Cancer